The efficacy of adenovirus (Ad)-based gene therapy of solid tumors, such as prostate cancer, is limited. One of the many problems is that the virus infects many different cell types in the body, resulting in high toxicity, whereas the target cancer cells are often less prone to wild-type Ad infection. Our aim was to develop genetically de- and retargeted Ad vectors to reduce off-target effects and increase target infection for prostate cancer. We have previously reported an Ad5 vector specific for the cancer-associated receptor Her2/neu, created by inserting Her2/neu-reactive Affibody® molecules (ZH) into the HI loop of a coxsackievirus and adenovirus receptor binding-ablated fiber (Ad[ZH/1]). In addition to virus retargeting to Her2/neu, this virus was further modified from wild-type Ad by changing the RGD motif in the penton base to EGD and by substitution of the KKTK motif in the third shaft repeat to RKSK, resulting in the vector Ad[ZH/3]. The ZH-containing vectors could be produced to high titers and were specific for their target, resulting in efficient infection and killing of Her2/neu-positive androgen-dependent PC346C prostate cancer cells in vitro. Here we show that the oncolytic Ad[ZH/3] vector significantly prolonged survival time and reduced serum prostate-specific antigen levels in an orthotopic prostate tumor model in nude mice to the same extent as wild-type Ad5. Our results show that Her2/neu targeting using Ad-based vectors for prostate cancer is feasible and may serve as a basis for the development of gene therapy of human prostate cancer as well as other Her2/neu-expressing cancers.
Bayo-PuxanN., CascalloM., GrosA.et al.2006. Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J. Gen. Virol., 87:2487–2495.
4.
Bayo-PuxanN., Gimenez-AlejandreM., Lavilla-AlonSOS.et al.2009. Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting. Hum. Gene Ther., 20:1214–1221.
5.
BergelsonJ.M., CunninghamJ.A., DroguettG.et al.1997. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science, 275:1320–1323.
6.
BernhardH., NeudorferJ., GebhardK.et al.2008. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol. Immunother., 57:271–280.
7.
CardinA.D., WeintraubH.J.1989. Molecular modeling of protein–glycosaminoglycan interactions. Arteriosclerosis, 9:21–32.
8.
ChengW.S., DzojicH., NilssonB.et al.2006. An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer. Cancer Gene Ther., 13:13–20.
9.
DechecchiM.C., TamaniniA., BonizzatoA., CabriniG.2000. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology, 268:382–390.
10.
de VrijJ., WillemsenR.A., LindholmL.et al.2010. Adenovirus-derived vectors for prostate cancer gene therapy. Hum. Gene Ther., 21:795–805.
11.
Di PaoloN.C., KalyuzhniyO., ShayakhmetovD.M.2007. Fiber shaft-chimeric adenovirus vectors lacking the KKTK-motif efficiently infect liver cells in vivo. J. Virol., 81:12249–2259.
12.
Elsasser-BeileU., BuhlerP., WolfP.2009. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr. Drug Targets, 10:118–125.
13.
El SheikhS.S., DominJ., AbelP.et al.2004. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia, 6:846–853.
FreytagS.O., StrickerH., PeggJ.et al.2003. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res., 63:7497–7506.
16.
HenningP., MagnussonM.K., GunneriussonE.et al.2002. Genetic modification of adenovirus 5 tropism by a novel class of ligands based on a three-helix bundle scaffold derived from staphylococcal protein A. Hum. Gene Ther., 13:1427–1439.
HilemanR.E., FrommJ.R., WeilerJ.M., LinhardtR.J.1998. Glycosaminoglycan–protein interactions: Definition of consensus sites in glycosaminoglycan binding proteins. Bioessays, 20:156–167.
19.
HudisC.A.2007. Trastuzumab: Mechanism of action and use in clinical practice. N. Engl. J. Med., 357:39–51.
20.
KellyE., RussellS.J.2007. History of oncolytic viruses: Genesis to genetic engineering. Mol. Ther., 15:651–659.
21.
KraaijR., van WeerdenW.M., De RidderC.M.et al.2002. Validation of transrectal ultrasonographic volumetry for orthotopic prostate tumours in mice. Lab. Anim., 36:165–172.
22.
KreppelF., GackowskiJ., SchmidtE., KochanekS.2005. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol. Ther., 12:107–117.
23.
KuppenP.J., Van der EbM.M., JongesL.E.et al.2001. Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer. Histochem. Cell Biol., 115:67–72.
24.
KusterK., KoschelA., RohwerN.et al.2010. Downregulation of the coxsackie and adenovirus receptor in cancer cells by hypoxia depends on HIF-1αCancer Gene Ther., 17:141–146.
25.
LangS.H., SmithJ, HydeC.et al.2006. Differentiation of prostate epithelial cell cultures by Matrigel/stromal cell glandular reconstruction. In Vitro Cell Dev. Biol. Anim., 42:273–280.
26.
LiZ.Y., NiS., YangX.et al.2004. Xenograft models for liver metastasis: Relationship between tumor morphology and adenovirus vector transduction. Mol. Ther., 9:650–657.
27.
LimpensJ., SchroderF.H., De RidderC.M.et al.2006. Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice. J. Nutr., 136:1287–1293.
28.
MagnussonM.K., HongS.S., BoulangerP., LindholmL.2001. Genetic retargeting of adenovirus: Novel strategy employing “deknobbing” of the fiber. J. Virol., 75:7280–7289.
29.
MagnussonM.K., HenningP., MyhreS.et al.2007. Adenovirus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2/neu. Cancer Gene Ther., 14:468–479.
30.
MaitlandN., ChambersK., GeorgopoulosL.et al.2010. Gene transfer vectors targeted to human prostate cancer: Do we need better preclinical testing systems?Hum. Gene Ther., 21:815–827.
31.
MaitlandN.J., MacintoshC.A., SchmitzC., LangS.H.2004. Immortalization of human prostate cells with the human papillomavirus type 16 E6 gene. Methods Mol. Med, 88:275–285.
32.
MarquesR.B., DitsN.F., Erkens-SchulzeS.et al.2010. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PloS One, 5:e13500.
33.
MillsonA., SuliA., HartungL.et al.2003. Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification. J. Mol. Diagn., 5:184–190.
34.
MorganR.A., YangJ.C., KitanoM.et al.2010. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther., 18:843–851.
35.
MorrisM.J., ReuterV.E., KellyW.K.et al.2002. HER-2 profiling and targeting in prostate carcinoma. Cancer, 94:980–986.
36.
MyhreS., HenningP., FriedmanM.et al.2009. Re-targeted adenovirus vectors with dual specificity: Binding specificities conferred by two different Affibody molecules in the fiber. Gene Ther., 16:252–261.
37.
NahtaR., EstevaF.J.2003. HER-2-targeted therapy: Lessons learned and future directions. Clin. Cancer Res., 9:5078–5084.
38.
NetoA.S., Tobias-MachadoM., WroclawskiM.L.et al.2010. Her-2/neu expression in prostate adenocarcinoma: A systematic review and meta-analysis. J. Urol., 184:842–850.
39.
NilssonB., MoksT., JanssonB.et al.1987. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng., 1:107–113.
40.
NordK., GunneriussonE., RingdahlJ.et al.1997. Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain. Nat. Biotechnol., 15:772–777.
41.
NordbergE., OrlovaA., FriedmanM.et al.2008. In vivo and in vitro uptake of 111In, delivered with the Affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. Oncol. Rep., 19:853–857.
42.
OrlovaA., RosikD., SandstromM.et al.2007. Evaluation of [111/114mIn]CHX-A′′-DTPA-ZHER2:342, an Affibody ligand conjugate for targeting of HER2-expressing malignant tumors. Q. J. Nucl. Med. Mol. Imaging.
43.
PandhaH.S., StockwinL.H., EatonJ.et al.2003. Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: Implications for gene therapy strategies. Prostate Cancer Prostatic Dis., 6:6–11.
44.
Piccart-GebhartM.J., ProcterM., Leyland-JonesB.et al.2005. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med., 353:1659–1672.
45.
PressM.F., Cordon-CardoC., SlamonD.J.1990. Expression of Her2-/Neu proto-oncogene in normal human adult and fetal tissues. Oncogene, 7:953–962.
46.
RauenK.A., SudilovskyD., LeJ.L.et al.2002. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy. Cancer Res., 62:3812–3818.
47.
ReidA.H., AttardG., DanilaD.C.et al.2010. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol., 28:1489–1495.
48.
RembrinkK., RomijnJ.C., Van der KwastT.H.et al.1997. Orthotopic implantation of human prostate cancer cell lines: A clinically relevant animal model for metastatic prostate cancer. Prostate, 31:168–174.
SignorettiS., MontironiR., ManolaJ.et al.2000. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst., 92:1918–1925.
51.
SimonR., NocitoA., HubscherT.et al.2001. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J. Natl. Cancer Inst., 93:1141–1146.
52.
SlamonD.J., GodolphinW., JonesL.A.et al.1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244:707–712.
53.
SmallE.J., BokR., ReeseD.M.et al.2001. Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Semin. Oncol., 28:71–76.
54.
SmithT.A., IdamakantiN., Marshall-NeffJ.et al.2003a. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum. Gene Ther., 14:1595–1604.
55.
SmithT.A., IdamakantiN., RollenceM.L.et al.2003b. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum. Gene Ther., 14:777–787.
56.
SwiftS.L., BurnsJ.E., MaitlandN.J.2010. Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer. Cancer Res., 70:347–356.
57.
TannockI.F., De WitR., BerryW.R.et al.2004. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med., 351:1502–1512.
58.
van der Heul-NieuwenhuijsenL., DitsN.F., JensterG.2009. Gene expression of forkhead transcription factors in the normal and diseased human prostate. BJU Int., 103:1574–1580.
59.
van WeerdenW.M., De RidderC.M., VerdaasdonkC.L.et al.1996. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am. J. Pathol., 149:1055–1062.
60.
VivesR.R., Lortat-JacobH., FenderP.2006. Heparan sulphate proteoglycans and viral vectors: Ally or foe?Curr. Gene Ther., 6:35–44.
61.
WickhamT.J., MathiasP., ChereshD.A., NemerowG.R.1993. Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment. Cell, 73:309–319.
62.
WikmanM., SteffenA.C., GunneriussonE.et al.2004. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng. Des. Sel., 18:18.
63.
WortmannA., VohringerS., EnglerT.et al.2008. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther., 16:154–162.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
